Short Interest in American Renal Associates Holdings, Inc (NYSE:ARA) Increases By 44.1%

American Renal Associates Holdings, Inc (NYSE:ARA) was the target of a significant increase in short interest in July. As of July 14th, there was short interest totalling 1,898,759 shares, an increase of 44.1% from the June 30th total of 1,317,948 shares. Based on an average daily trading volume, of 310,324 shares, the days-to-cover ratio is currently 6.1 days. Currently, 6.5% of the shares of the stock are sold short.

ARA has been the subject of several research analyst reports. Zacks Investment Research lowered American Renal Associates Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Wells Fargo & Company raised American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $25.50.

American Renal Associates Holdings (NYSE:ARA) opened at 14.10 on Friday. The company’s market capitalization is $441.12 million. American Renal Associates Holdings has a 52-week low of $13.74 and a 52-week high of $25.42. The company has a 50-day moving average price of $16.79 and a 200 day moving average price of $17.94.

American Renal Associates Holdings (NYSE:ARA) last posted its earnings results on Tuesday, August 8th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.04. The company had revenue of $185.99 million during the quarter, compared to the consensus estimate of $188.23 million. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. American Renal Associates Holdings’s quarterly revenue was up .2% compared to the same quarter last year. Equities research analysts anticipate that American Renal Associates Holdings will post $0.54 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Citigroup Inc. increased its position in shares of American Renal Associates Holdings by 1,876.9% in the second quarter. Citigroup Inc. now owns 8,046 shares of the company’s stock worth $149,000 after buying an additional 7,639 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of American Renal Associates Holdings by 19.7% in the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after buying an additional 1,443 shares during the period. Atria Investments LLC purchased a new position in shares of American Renal Associates Holdings during the first quarter worth $181,000. Dimensional Fund Advisors LP purchased a new position in shares of American Renal Associates Holdings during the second quarter worth $230,000. Finally, Oxford Asset Management bought a new position in American Renal Associates Holdings during the first quarter valued at $237,000. Institutional investors and hedge funds own 90.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/08/19/american-renal-associates-holdings-inc-nyseara-short-interest-up-44-1-in-july-updated-updated.html.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

What are top analysts saying about American Renal Associates Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for American Renal Associates Holdings Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit